4//SEC Filing
KRANZLER JAY D 4
Accession 0000716054-09-000019
CIK 0000716054other
Filed
Aug 3, 8:00 PM ET
Accepted
Aug 4, 1:35 PM ET
Size
10.9 KB
Accession
0000716054-09-000019
Insider Transaction Report
Form 4
KRANZLER JAY D
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Options (right to buy)
2009-08-03−75,000→ 37,874 totalExercise: $2.51From: 2007-03-27Exp: 2013-03-27→ Common Stock (75,000 underlying) - Exercise/Conversion
Common Stock
2009-08-03$2.51/sh+75,000$188,250→ 171,742 total(indirect: By Trust) - Sale
Common Stock
2009-08-03$8.69/sh−75,000$651,848→ 96,742 total(indirect: By Trust)
Holdings
- 625
Common Stock
- 204,412(indirect: By 401(k))
Common Stock
Footnotes (4)
- [F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2009.
- [F2]The weighted average sale price for the transaction reported was $8.6913, the range of prices were between $8.53 and $8.95. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- [F3]The shares subject to the option were fully vested as of March 27, 2007.
- [F4]Includes 72,187 shares acquired on June 30, 2009 under the Issuer's 401(k) Plan, of which the Reporting Person is the Trustee and has voting power over such shares.
Documents
Issuer
CYPRESS BIOSCIENCE INC
CIK 0000716054
Entity typeother
Related Parties
1- filerCIK 0001055666
Filing Metadata
- Form type
- 4
- Filed
- Aug 3, 8:00 PM ET
- Accepted
- Aug 4, 1:35 PM ET
- Size
- 10.9 KB